No Data
Recursion and Exscientia, Two Leaders in the AI Drug Discovery Space, Have Officially Combined to Advance the Industrialization of Drug Discovery
BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $12
Hold Rating Recommended for Recursion Pharmaceuticals Post-Merger With Exscientia: Upside Potential Amidst Clinical Uncertainties
KeyBanc Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $12
Cathie Wood's ARK Investment Buys 383K Shares of Recursion Pharmaceuticals Today
Recursion Pharmaceuticals Price Target Maintained With a $11.00/Share by Needham
No Data
No Data
Space Dust : all ai needs for drug discovery is to find old literature before pharma took over the AMA. pharma is just synthesizing old natural cures and putting a patent on them..
ELEVENjonny :
骨神 : Today down due to nivadia